Incyte Shares Fall After Weak 2026 Revenue Forecast Sparks Growth Concerns
Incyte shares fell Tuesday after a weak 2026 revenue forecast missed estimates. The outlook raises concerns about growth ahead of a key patent cliff in 2028.
Insights:
Incyte Corporation announced on February 10, 2026, that its revenue guidance for 2026 is expected to be lower than Wall Street estimates, a primary trigger that prompted a drop in the company's shares. The US 
US-based pharmaceutical firm forecast total 2026 revenue to range between $4.77 billion and $4.94 billion. This projection is materially below the $5.52 billion consensus estimate previously cited by analysts at LSEG and BMO.
US-based pharmaceutical firm forecast total 2026 revenue to range between $4.77 billion and $4.94 billion. This projection is materially below the $5.52 billion consensus estimate previously cited by analysts at LSEG and BMO.
